Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NTRA FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm's Attorneys Before June 27th Application Deadline in Securities Class Action


San Francisco, California--(Newsfile Corp. - June 26, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now.

Class Period: Feb. 26, 2020 - Apr. 19, 2022

Lead Plaintiff Deadline: June 27, 2022

Contact An Attorney


Natera, Inc.(NASDAQ: NTRA) Securities Fraud Class Action:

Defendants have repeatedly claimed that its screening test for kidney transplant failure ("Prospera") was superior to competitors' tests and that its non-invasive prenatal test ("Panorama") was reliable.

According to the complaint, Defendants misrepresented or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the company was exposed to substantial legal and regulatory risks; and, (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth.

On Jan. 1, 2022, The New York Times reported that positive results for genetic disorders such as DiGeorge and Prader-Willi syndromes when using Natera's test are incorrect more than 80% of the time.

On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama.

On Mar. 9, 2022, analyst Hindenburg Research published a scathing report concluding that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."

On Mar. 14, 2022, a federal jury found that Natera intentionally and willfully misled the public by utilizing false advertisements to market Prospera as being more effective than CareDx's competing AlloSure test.

"We're focused on investors' losses and proving Natera misrepresented the reliability and superiority of its tests," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Natera and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Natera should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email mailto:

# # #

Reed Kathrein, 844-916-0895

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.

To view the source version of this press release, please visit